Cancer medicine · 2025
Resveratrol: Sensitising CD44+ Cervical Cancer Cells to Carboplatin and Mitigating Metastasis.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Sousa Cayleigh, Eksteen Carla, Engelbrecht Anna-Mart
Аннотация
BACKGROUND: Cervical cancer remains a leading cause of cancer-related mortality among women globally. Persistent infection with high-risk human papillomavirus drives cervical carcinogenesis, and treatment outcomes are frequently challenged by metastasis and chemoresistance. The transmembrane glycoprotein cluster of differentiation 44 (CD44), a marker associated with cancer stem cells (CSCs), has emerged as a critical mediator of both processes in cervical cancer.
OBJECTIVE: This review aims to critically evaluate current evidence on the role of CD44 in cervical cancer progression, metastasis, and treatment resistance. It also explores the potential of resveratrol, a naturally occurring polyphenol with known anticancer properties, as a chemo-sensitizing agent to carboplatin therapy.
METHODS: A comprehensive review of the literature was conducted using databases such as PubMed, Google Scholar, and Scopus to identify studies that investigate CD44-mediated mechanisms in cervical cancer, as well as the modulatory and mechanistic effects of resveratrol on CD44 and chemoresistance across various cancer types.
RESULTS: CD44 has been consistently implicated in promoting drug resistance, epithelial-to-mesenchymal transition (EMT), and stemness in cervical cancer. Resveratrol has demonstrated antimetastatic and chemo-sensitizing effects in several malignancies, such as colorectal and breast cancers, often through modulation of CD44 and associated pathways. However, direct evidence in cervical cancer remains limited.
CONCLUSION: Current findings suggest a promising therapeutic avenue for combining resveratrol with carboplatin to overcome CD44-mediated treatment resistance and metastasis in cervical cancer. Nonetheless, further cervical-specific studies are needed to validate this approach. A clearer understanding of this relationship may facilitate lower chemotherapy dosing, reduced toxicity, and improved clinical outcomes.
OBJECTIVE: This review aims to critically evaluate current evidence on the role of CD44 in cervical cancer progression, metastasis, and treatment resistance. It also explores the potential of resveratrol, a naturally occurring polyphenol with known anticancer properties, as a chemo-sensitizing agent to carboplatin therapy.
METHODS: A comprehensive review of the literature was conducted using databases such as PubMed, Google Scholar, and Scopus to identify studies that investigate CD44-mediated mechanisms in cervical cancer, as well as the modulatory and mechanistic effects of resveratrol on CD44 and chemoresistance across various cancer types.
RESULTS: CD44 has been consistently implicated in promoting drug resistance, epithelial-to-mesenchymal transition (EMT), and stemness in cervical cancer. Resveratrol has demonstrated antimetastatic and chemo-sensitizing effects in several malignancies, such as colorectal and breast cancers, often through modulation of CD44 and associated pathways. However, direct evidence in cervical cancer remains limited.
CONCLUSION: Current findings suggest a promising therapeutic avenue for combining resveratrol with carboplatin to overcome CD44-mediated treatment resistance and metastasis in cervical cancer. Nonetheless, further cervical-specific studies are needed to validate this approach. A clearer understanding of this relationship may facilitate lower chemotherapy dosing, reduced toxicity, and improved clinical outcomes.